Telomir Pharmaceuticals Inc
Company Profile
Business description
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer’s disease, osteoarthritis, and others.
Contact
100 South East, 2nd Street
Suite 200, No.1009
MiamiFL33131
USAT: +1 786 396-6723
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
stocks
Impact of ANZ’s huge fine
stocks
Acquisition a sign of weakness for overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,094.90 | 27.60 | -0.30% |
| CAC 40 | 7,797.20 | 21.02 | -0.27% |
| DAX 40 | 23,301.42 | 27.82 | -0.12% |
| Dow JONES (US) | 45,757.90 | 125.55 | -0.27% |
| FTSE 100 | 9,217.61 | 21.95 | 0.24% |
| HKSE | 26,908.39 | 469.88 | 1.78% |
| NASDAQ | 22,333.96 | 14.79 | -0.07% |
| Nikkei 225 | 44,790.38 | 111.89 | -0.25% |
| NZX 50 Index | 13,228.38 | 6.51 | -0.05% |
| S&P 500 | 6,606.76 | 8.52 | -0.13% |
| S&P/ASX 200 | 8,818.50 | 30.00 | -0.34% |
| SSE Composite Index | 3,876.34 | 14.48 | 0.37% |